AbbVie submits regulatory applications for Skyrizi (risankizumab) in psoriatic arthritis to FDA and EMA


7 April 2021 - Submissions supported by two Phase 3 studies in patients with active psoriatic arthritis in which Skyrizi demonstrated improved skin and joint symptoms and physical function, with a greater proportion of patients achieving minimal disease activity versus placebo.

AbbVie today announced that it has submitted applications seeking approval for Skyrizi (risankizumab-rzaa, 150 mg) to the U.S. FDA and for Skyrizi (risankizumab, 150 mg) to the EMA for the treatment of adults with active psoriatic arthritis.

Read AbbVie press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Europe , US , Dossier